Clinical Trial Update: Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of ipilimumab (Yervoy) and pegylated interferon alfa-2b (Sylatron) in unresectable stage III/IV melanoma has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Sylatron (peginterferon alfa-2b)
• Yervoy (ipilimumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2017-04-28